Alaunos Therapeutics, Inc. (TCRT) Revenue History
Annual and quarterly revenue from 2001 to present
TCRT Revenue Over Time (2001–2025)
TCRT Revenue Growth History
7 of 14 years with positive growth- FY2001 revenue growth
- N/A
- FY2002 revenue growth
- +48.9%
- FY2003 revenue growth
- -100.0%
- FY2004 revenue growth
- N/A
- FY2005 revenue growth
- N/A
- FY2006 revenue growth
- N/A
- FY2007 revenue growth
- N/A
- FY2008 revenue growth
- N/A
- FY2009 revenue growth
- N/A
- FY2010 revenue growth
- N/A
- FY2011 revenue growth
- N/A
- FY2012 revenue growth
- +19.9%
- FY2013 revenue growth
- +0.0%
- FY2014 revenue growth
- +71.6%
- FY2015 revenue growth
- +215.5%
- FY2016 revenue growth
- +58.4%
- FY2017 revenue growth
- -6.9%
- FY2018 revenue growth
- -97.7%
- FY2019 revenue growth
- -100.0%
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- +634.2%
- FY2023 revenue growth
- -99.8%
- FY2024 revenue growth
- +100.0%
- FY2025 revenue growth
- -50.0%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | -100.0% |
| Q4 2025 | $3K | -25.0% |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | -100.0% |
| Q1 2025 | $2K | +100.0% |
| Q4 2024 | $4K | +300.0% |
| Q3 2024 | $0 | — |
| Q2 2024 | $4K | +0.0% |
Multi-year avg. share of annual revenue by fiscal quarter
TCRT Revenue Analysis (2001–2025)
Current Revenue & Growth
As of June 23, 2026, Alaunos Therapeutics, Inc. (TCRT) generated trailing twelve-month (TTM) revenue of $3,000, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q1 2026) recorded $0 in revenue, down 100.0% sequentially.
Historical Growth Trajectory
TCRT's historical revenue data shows a 3-year CAGR of -88.0%. Alaunos Therapeutics, Inc.'s highest annual revenue of $6.9 million was recorded in 2016.
Peer Comparison
Compared to Healthcare sector peers — including IOVA (+34.3% YoY), FATE (-52.6% YoY), and TCRX (+106.7% YoY) — TCRT has underperformed the peer group in revenue growth. Compare TCRT vs IOVA →
TCRT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TCRTCurrent | $3,000 | -100.0% | - | -84500.0% | |
 IOVA | $264M | +34.3% | - | -153.1% | |
 FATE | $7M | -52.6% | -26.7% | -2222.4% | |
 TCRX | $10M | +106.7% | +56.9% | -1315.4% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% |
TCRT Historical Revenue Data (2001–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $5K | -50.0% | $5K | 100.0% | $-4,225,000 | -84500.0% |
| 2024 | $10K | +100.0% | $10K | 100.0% | $-4,812,000 | -48120.0% |
| 2023 | $5K | -99.8% | $-4,798,000 | -95960.0% | $-34,267,000 | -685340.0% |
| 2022 | $2.9M | +634.2% | $2.9M | 100.0% | $-35,105,000 | -1201.4% |
| 2021 | $398K | - | $398K | 100.0% | $-77,549,000 | -19484.7% |
| 2020 | $0 | - | $-1,128,000 | - | $-80,361,000 | - |
| 2019 | $0 | -100.0% | $-629,000 | - | $-57,858,000 | - |
| 2018 | $146K | -97.7% | $146K | 100.0% | $-53,906,000 | -36921.9% |
| 2017 | $6.4M | -6.9% | $6.4M | 100.0% | $-53,493,000 | -837.3% |
| 2016 | $6.9M | +58.4% | $6.9M | 100.0% | $-165,307,000 | -2409.4% |
| 2015 | $4.3M | +215.5% | $4.3M | 100.0% | $-120,100,000 | -2772.4% |
| 2014 | $1.4M | +71.6% | $1.4M | 100.0% | $-43,499,000 | -3168.2% |
| 2013 | $800K | +0.0% | $800K | 100.0% | $-57,713,000 | -7214.1% |
| 2012 | $800K | +19.9% | $800K | 100.0% | $-102,169,000 | -12771.1% |
| 2011 | $667K | - | $667K | 100.0% | $-71,400,000 | -10704.6% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
25+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TCRT — Frequently Asked Questions
Quick answers to the most common questions about buying TCRT stock.
Is TCRT's revenue growth accelerating or slowing?
TCRT revenue is declining -100.0% year-over-year. TTM revenue fell to $3000.00, contrasting with the 5-year CAGR of N/A. The reversal reflects either macro headwinds or company-specific challenges.
What is TCRT's revenue history from 2001 to 2026?
Alaunos Therapeutics, Inc. (TCRT) revenue history spans 2001 to 2026. TTM revenue as of 2026 is $3000.00, growing at -100.0% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is TCRT's long-term revenue growth rate (CAGR)?
Alaunos Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -100.0% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for TCRT.
Why does TCRT's quarterly revenue fluctuate?
TCRT quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Alaunos Therapeutics, Inc.'s revenue data from 2001 to 2026 shows full historical quarterly detail on this page.
How is TCRT's revenue distributed by segment?
TCRT reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does TCRT's revenue compare to industry peers?
Alaunos Therapeutics, Inc. (TCRT) with TTM revenue of $3000.00 and -100.0% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.